HemaQuest expands Phase II remit for HQK-1001 in sickle cell disease
This article was originally published in Scrip
Executive Summary
HemaQuest, a US biotech focused on developing small-molecule therapeutics for haemoglobin diseases, has expanded the Phase II programme for its lead compound, HQK-1001, in sickle cell disease with a new trial aimed at establishing safety and tolerability at higher dose levels and over a longer course of therapy.